Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Gentamicin: adverse event reports

All products with this active ingredient · no approved product with exactly this set

223reports naming this ingredient, 2002–20260% of all reports · about 9 a year
61reports, 12 months to March 202635 in the 12 months before
64.2%classed serious, as reportedof 201 reports stating it
16.1%record death or euthanasia, as reported36 reports
66.8%of reports concern dogs0% of all dog reports

223 adverse event reports in FDA's database list a drug whose active ingredient is recorded as gentamicin. The earliest was received in May 2002, the latest in March 2026. No FDA-approved product has exactly this set of ingredients; the ingredient field of a report can be incomplete.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 61 reports named it, up 74% from 35 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 9 reports a year and 0% of all 1,357,245 reports (0% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The most frequently coded terms are lethargy (16.1%), other abnormal test result NOS (12.1%) and vomiting (11.7%). A report can list several signs, so shares add to more than 100%; 606 different terms appear across these reports. Lethargy appears in 16.1% of these reports, a larger share than in the pooled reports for every drug containing gentamicin (9.2%).

66.8% of reports concern dogs. Not every report describes illness: 13% were filed wholly or partly as lack of expected effectiveness and 5.8% as product or packaging defects. Of reports that state seriousness, 64.2% were classed as serious, and 16.1% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog88 · peak 6
Aug 2021: 1Jan 2022: 3Apr 2022: 1May 2022: 1Aug 2022: 1Nov 2022: 1Apr 2023: 1Jul 2023: 2Aug 2023: 1Sep 2023: 3Dec 2023: 1Jan 2024: 1Feb 2024: 1Apr 2024: 1May 2024: 3Jun 2024: 3Jul 2024: 3Aug 2024: 1Sep 2024: 3Oct 2024: 4Dec 2024: 1Jan 2025: 1Feb 2025: 4Mar 2025: 1Apr 2025: 4May 2025: 2Jun 2025: 4Jul 2025: 4Aug 2025: 3Sep 2025: 5Oct 2025: 3Nov 2025: 4Dec 2025: 4Jan 2026: 4Feb 2026: 6Mar 2026: 22022202320242025
Cat9 · peak 2
Nov 2022: 1Feb 2023: 1Oct 2024: 1Nov 2024: 1Dec 2024: 1Oct 2025: 1Dec 2025: 2Jan 2026: 12022202320242025
Horse21 · peak 4
Jan 2022: 1May 2022: 1Jul 2022: 1Feb 2023: 1Oct 2023: 1Jan 2024: 1Feb 2024: 1May 2024: 1Jul 2024: 1Oct 2024: 1Dec 2024: 1Jul 2025: 1Sep 2025: 1Dec 2025: 3Jan 2026: 4Mar 2026: 12022202320242025
Other9 · peak 1
Sep 2023: 1Jan 2024: 1Feb 2024: 1Mar 2024: 1Nov 2024: 1Dec 2024: 1Mar 2025: 1Apr 2025: 1Jan 2026: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

025492002: 120022003: 12009: 120092012: 62013: 2020132014: 132015: 1020152016: 142017: 620172018: 102019: 620192020: 72021: 220212022: 112023: 1220232024: 352025: 4920252026: 19

2026 covers reports received through March 2026 only.

Signs listed in reports

share of gentamicin reports listing the termall drugs containing gentamicinall dog reports

  1. Lethargy[unusually tired or inactive]16.1%36
  2. Other abnormal test result NOS[abnormal laboratory result, type not specified]12.1%27
  3. Vomiting11.7%26
  4. Diarrhoea[diarrhea]11.2%25
  5. Death by euthanasia[the animal was euthanized]9.4%21
  6. Lack of efficacy - NOS[the product did not have the expected effect]8.1%18
  7. Pain NOS[NOS: not otherwise specified]6.7%15
  8. Death6.3%14
  9. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]5.8%13
  10. Emesis[vomiting]5.8%13
  11. Fever5.8%13
  12. Seizure NOS[seizure, type not specified]5.8%13
  13. Anorexia[not eating]4.9%11
  14. Behavioural disorder NOS[behaviour change, type not specified]4.9%11
  15. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]4.5%10
  16. Pruritus[itching]4.5%10
  17. Emesis (multiple)[vomiting more than once]4%9
  18. Ataxia[unsteady, uncoordinated movement]3.6%8
  19. Elevated serum alkaline phosphatase (ALP)[a liver and bone enzyme above the normal range]3.6%8
  20. Lymphopenia[low lymphocyte count]3.6%8
  21. Otitis externa[outer ear inflammation]3.6%8
  22. Polydipsia[drinking more than usual]3.6%8

Top 30 of 606 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal30%67
Recovered with Sequela1.3%3
Ongoing26%58
Died7.6%17
Euthanized9.4%21
Outcome Unknown22.4%50

What kind of report it was

Safety issue81.2%181
Lack of expected effectiveness4.9%11
Both safety and lack of expected effectiveness8.1%18
Manufacturing or product defect5.8%13
Other0%0

Coloured bar: reports naming gentamicin. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog66.8%149
Horse16.6%37
Cat9%20
Pig1.3%3
Donkey0.4%1

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year4.9%11
1 to 3 years19.3%43
4 to 7 years18.8%42
8 to 11 years21.5%48
12 years and over25.6%57
Age not given9.9%22

Weight of the animal

Under 5 kg (11 lb)9.9%22
5 to 9.9 kg (11–22 lb)16.6%37
10 to 24.9 kg (22–55 lb)18.4%41
25 to 44.9 kg (55–99 lb)23.8%53
45 kg and over (99 lb+)14.3%32
Weight not given17%38

Route of administration stated in reports: topical (71), intravenous (24), auricular (otic) (9), ophthalmic (7), other (5), intramuscular (3).

In context

MeasureGentamicinAll drugs containing gentamicinAll dog reportsAll reports
Reports2231,757985,6751,357,245
Share of that pool's reports naming this drug—12.7%0%0%
Classed serious, of reports stating it64.2%40.3%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports161.4605563.8
Filed as lack of expected effectiveness (wholly or partly)13%——23%
Top term, share of reportsLethargy 16.1%9.2%7.9%—

The gentamicin pool is every report naming gentamicin alone or in any combination; this single-ingredient set accounts for 12.7% of it. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Active ingredientsReportsLatest 12 months
Clotrimazole + Gentamicin1,32169
Clotrimazole + Gentamicin + Mometasone furoate1651

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

FDA-approved products (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 30 Sep 2026; nothing on this page says which of these products, if any, a report concerned.

No approved product has exactly this set of active ingredients. The ingredient field of a report can be incomplete; these approved products contain all of the ingredients named here, together with others.

Trade nameActive ingredientsSponsorApproved forApplication
Mometamax SingleGentamicin, Mometasone furoate, posaconazoleIntervet, Inc.DogsNADA 141-600

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about gentamicin reports

How many adverse event reports has FDA received for gentamicin?

223 reports record a drug with gentamicin as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 61 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

What signs are reported most often?

lethargy (16.1%), other abnormal test result NOS (12.1%), vomiting (11.7%), diarrhoea (11.2%) and death by euthanasia (9.4%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (66.8%), horse (16.6%) and cat (9%). Among single-breed animals the most frequent labels are Domestic Shorthair, Labrador Retriever, Quarter Horse and Boston Terrier; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

61 reports in the 12 months to March 2026, up 74% from 35 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that gentamicin harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of gentamicin?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 30 Sep 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.